Researchers developed a tumor-conditional interleukin-12 (pro-IL-12), which masked IL-12 with selective extracellular receptor–binding domains of the IL-12 receptor while preferentially and persistently activating tumor-infiltrating lymphocytes after being unmasked by matrix metalloproteinases expressed by tumors.
[Science Immunology]
7992332
{7992332:BBBBBBBB}
apa
50
1
170528
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/